Multiple myeloma presenting as bilateral orbital proptosis

Malik, Archana; Narang, Subina; Handa, Uma; Sood, Sunandan
November 2009
Indian Journal of Ophthalmology;Nov2009, Vol. 57 Issue 5, p393
Academic Journal
Case Study
A 58-year-old-man presented with painful rapidly progressive bilateral proptosis with restricted ocular movements of 15 days duration. There was history of significant weight loss in the recent past. Computed tomography scan of the head and orbit revealed bilateral multiple, well-defined, round, soft tissue masses, isointense with muscles in intraconal and extraconal space. Fine needle aspiration cytology and incision biopsy from the lesion, urine for Bence-Jones proteins and immunofixation clinched the diagnosis of multiple myeloma. Skeletal survey did not reveal any bony involvement. The diagnosis of multiple myeloma should be kept in mind in cases of bilateral proptosis. Bony involvement is not universal in cases of orbital myeloma. Early diagnosis can be established with extensive biochemical and histopathological investigations and timely treatment is life saving for these patients.


Related Articles

  • Auer rod-like inclusions in plasma cells in multiple myeloma. Wai Khoon Ho; Daniela Zantomio // Journal of Clinical Pathology;Jun2014, Vol. 67 Issue 6, p547 

    The article presents a case study of a female patient who presented to physicians with bone pain. A discussion of diagnostic testing which was conducted on the patient, and resulted in her receiving a diagnosis of multiple myeloma with Auer rod-like inclusions in her plasma cells, is presented.

  • Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival. Wuillème-Toumi, S.; Robillard, N.; Gomez, P.; Moreau, P.; Le Gouill, S.; Avet-Loiseau, H.; Harousseau, J.-L.; Amiot, M.; Bataille, R. // Leukemia (08876924);Jul2005, Vol. 19 Issue 7, p1248 

    We and others have shown that Mcl-1 was essential for the survival of human myeloma cells in vitro. Furthermore, this antiapoptotic protein is upregulated by interleukin-6, which plays a critical role in multiple myeloma (MM). For these reasons, we have evaluated the expression of Mcl-1 in vivo...

  • Klinické aspekty „pravé“ nesekretorické formy mnohočetného myelomu. T., Pika; P., Lochman; P., Flodr; P., Mičková; M., Novák; Z., Jehlíková; A., Hamplová; J., Minařík; J., Bačovský; L., Kučerová; M., Jarošova; V., Ščudla // Transfusiology & Haematology Today / Transfuze a Hematologie Dne;2013, Vol. 19 Issue 1, p27 

    Non-secretory myeloma represents a less frequent variant of multiple myeloma. The development of electrophoretical methods and especially serum free light chain assessment has enabled the identification of secretion in patients formerly classified as non-secretory disease. Therefore,...

  • Clinical, Immunophenotypic, and Genetic Characterization of Small Lymphocyte–Like Plasma Cell Myeloma: A Potential Mimic of Mature B-Cell Lymphoma. Amy Heerema-McKenney // American Journal of Clinical Pathology;Feb2010, Vol. 133 Issue 2, p265 

    We reviewed bone marrow studies from 351 multiple myeloma (MM) cases, selecting 12 cases (3.4%) with predominantly small lymphocyte–like morphologic features resembling B-cell lymphoma, and correlated their genetic and clinical features. All exhibited a diffuse interstitial pattern of...

  • GRAND ROUNDS AT THE NATIONAL INSTITUTES OF HEALTH. Multiple Myeloma Precursor Disease. Landgren, Ola; Waxman, Adam Justin // JAMA: Journal of the American Medical Association;12/1/2010, Vol. 304 Issue 21, p2397 

    The article describes the case of a 72-year-old white man with multiple myeloma and an 11-year history of monoclonal gammopathy of undetermined significance (MGUS). During a follow-up visit in 2009, his laboratory values, which include creatinine, calcium and albumin increased. His skeletal...

  • An overview of multiple myeloma in dogs and cats. Sternberg, Rachel; Wypij, Jackie; Barger, Anne M. // Veterinary Medicine;Oct2009, Vol. 104 Issue 10, p468 

    The article discusses the presence of multiple myeloma in dogs and cats. It mentions that multiple myeloma is an uncommon lymphoproliferative disease in animals and its cause is largely unknown. It notes that the disease is a B cell malignancy which is depicted by the infiltration and growth of...

  • Melphalan and Myeloma. McArthur, James R.; Athens, John W.; Wintrobe, Maxwell M.; Cartwright, George E. // Annals of Internal Medicine;May70, Vol. 72 Issue 5, p665 

    Sixty-seven patients with symptomatic multiple myeloma were studied. Thirty-nine were treated with melphalan. The initial dose of 4 mg by mouth daily was reduced if the white blood count fell below 2,000 to 2,500/mma³. There were significant objective and subjective improvement and increased...

  • Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Štifter, Sanja; Babarovic, Emina; Valkovic, Toni; Seili-Bekafigo, Irena; Štemberger, Christophe; Nacinovic, Antica; Lucin, Ksenija; Jonjic, Nives // Diagnostic Pathology;2010, Vol. 5, p30 

    Background: Estimation of plasma cell infiltrates in bone marrow aspirates (BMA) and bone marrow biopsy (BMB) is a standard method in the diagnosis and monitoring of multiple myeloma (MM). Plasma cell fraction in the bone marrow is therefore critical for the classification and optimal clinical...

  • Treatment of plasma cell dyscrasias with lenalidomide. Dimopoulos, M A; Kastritis, E; Rajkumar, S V // Leukemia (08876924);Jul2008, Vol. 22 Issue 7, p1343 

    Lenalidomide is an immunomodulatory drug, structurally related to thalidomide, with pleiotropic activity including antiangiogenic and antineoplastic properties. It is the product of advances in our understanding of the biology of myeloma cells, their interactions with the microenvironment and of...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics